748 related articles for article (PubMed ID: 28667429)
1. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
3. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
5. Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes.
Plevris N; Jones GR; Jenkinson PW; Lyons M; Chuah CS; Merchant LM; Pattenden RJ; Watson EF; Ho GT; Noble CL; Din S; Shand AG; Arnott ID; Lees CW
Dig Dis Sci; 2019 Jun; 64(6):1660-1667. PubMed ID: 30535885
[TBL] [Abstract][Full Text] [Related]
6. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
Buer LC; Moum BA; Cvancarova M; Warren DJ; Medhus AW; Høivik ML
J Crohns Colitis; 2017 Mar; 11(3):297-304. PubMed ID: 27660339
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
[TBL] [Abstract][Full Text] [Related]
8. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
9. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Keil R; Wasserbauer M; Zádorová Z; Hajer J; Drastich P; Wohl P; Beneš M; Bojková M; Svoboda P; Konečný M; Falt P; Vaňásek T; Pešta M; Pešek F; Bouchner L; Koželuhová J; Novotný A; Bartůsková L; Špičák J
Scand J Gastroenterol; 2016 Sep; 51(9):1062-8. PubMed ID: 27002981
[TBL] [Abstract][Full Text] [Related]
10. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
[TBL] [Abstract][Full Text] [Related]
11. Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study.
Petitdidier N; Tannoury J; de'Angelis N; Gagniere C; Hulin A; Rotkopf H; Mesli F; Brunetti F; Sobhani I; Amiot A
Dig Liver Dis; 2019 Dec; 51(12):1652-1660. PubMed ID: 31718934
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
13. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F
Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795
[TBL] [Abstract][Full Text] [Related]
14. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
16. Experience with Biosimilar Infliximab (Remsima®) in Norway.
Jahnsen J; Kaasen Jørgensen K
Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
[TBL] [Abstract][Full Text] [Related]
17. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
Schreiber S; Ben-Horin S; Leszczyszyn J; Dudkowiak R; Lahat A; Gawdis-Wojnarska B; Pukitis A; Horynski M; Farkas K; Kierkus J; Kowalski M; Lee SJ; Kim SH; Suh JH; Kim MR; Lee SG; Ye BD; Reinisch W
Gastroenterology; 2021 Jun; 160(7):2340-2353. PubMed ID: 33676969
[TBL] [Abstract][Full Text] [Related]
18. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
Fiorino G; Manetti N; Armuzzi A; Orlando A; Variola A; Bonovas S; Bossa F; Maconi G; DʼIncà R; Lionetti P; Cantoro L; Fries W; Annunziata ML; Costa F; Terpin MM; Biancone L; Cortelezzi CC; Amato A; Ardizzone S; Danese S; Guidi L; Rizzuto G; Massella A; Andriulli A; Massari A; Lorenzon G; Ghione S; Kohn A; Ventra A; Annese V;
Inflamm Bowel Dis; 2017 Feb; 23(2):233-243. PubMed ID: 28092307
[TBL] [Abstract][Full Text] [Related]
19. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
20. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
